Skip to main content

Table 1 Clinicopathologic characteristics of the 39 enrolled patients

From: Prospective, longitudinal analysis of the gut microbiome in patients with locally advanced rectal cancer predicts response to neoadjuvant concurrent chemoradiotherapy

 

TRG0-1 (n = 22)

TRG2-3 (n = 17)

P Value

Age, years, mean (sd)

55.9 (12.6)

61.1 (11.3)

0.184

Sex

  

0.318

 Female

9

4

 

 Male

13

13

 

Body mass index, mean (sd)

23.5 (3.00)

23.1 (2.67)

0.626

Family history of cancer

  

0.704

 Yes

6

3

 

 No

16

14

 

Tumor length, cm

  

0.194

  ≤ 5

12

13

 

  > 5

10

4

 

Distance between anal verge and lower margin of tumor, cm

  

1

  ≤ 5

15

11

 

  > 5

7

6

 

Colorectal polyps

  

0.738

 Yes

7

7

 

 No

15

10

 

CEA level, ng/mL

  

0.193

  ≤ 5

12

5

 

  > 5

10

12

 

Induction chemotherapy*

  

0.334

 Yes

10

11

 

 No

12

6

 

Clinical T status

  

0.184

 T3

6

9

 

 T4

16

8

 

Clinical N status

  

0.054

 N1

14

5

 

 N2

8

12

 

Tumor differentiation

  

0.859

 Low

3

2

 

 Medium

16

14

 

 High

3

1

 

Vascular cancer thrombus

  

1

 Yes

3

3

 

 No

19

14

 

Nerve invasion

  

0.679

 Yes

4

2

 

 No

18

15

 
  1. Classification variables are described statistically by composition, with P values determined by Fisher's exact test. The continuous variables age and body mass index were confirmed to be normally distributed, and so the results are expressed as mean (standard deviation), with P values determined by t tests
  2. TRG, tumor regression grade (per the American Joint Committee on Cancer staging manual, 8th edn); CEA, carcinoembryonic antigen.
  3. *Induction chemotherapy consisted of oral capecitabine 1000 mg/m2 twice daily for 14 days and intravenous oxaliplatin 130 mg/m2 on day 1